These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 3285830

  • 21. Clinical efficacy of torasemide, a new diuretic agent, in patients with acute heart failure: a double blind comparison with furosemide.
    Stroobandt R, Dodion L, Kesteloot H.
    Arch Int Pharmacodyn Ther; 1982 Nov; 260(1):151-8. PubMed ID: 6762167
    [Abstract] [Full Text] [Related]

  • 22. Effect of inhaled furosemide and torasemide on bronchial response to ultrasonically nebulized distilled water in asthmatic subjects.
    Foresi A, Pelucchi A, Mastropasqua B, Cavigioli G, Carlesi RM, Marazzini L.
    Am Rev Respir Dis; 1992 Aug; 146(2):364-8. PubMed ID: 1489126
    [Abstract] [Full Text] [Related]

  • 23. [Comparison between torasemide and furosemide in the treatment of ascites in cirrhotic patients].
    Marelli A, Bodini P, Reggiani A, Quinzani M, Dizioli P, Tonghini L.
    Minerva Med; 1997 Mar; 88(3):109-15. PubMed ID: 9148226
    [Abstract] [Full Text] [Related]

  • 24. Torasemide. A review of its pharmacological properties and therapeutic potential.
    Friedel HA, Buckley MM.
    Drugs; 1991 Jan; 41(1):81-103. PubMed ID: 1706990
    [Abstract] [Full Text] [Related]

  • 25. Acute and chronic effects of torasemide in healthy volunteers.
    Lameire N, Dodion L.
    Arzneimittelforschung; 1988 Jan; 38(1A):167-71. PubMed ID: 3370064
    [Abstract] [Full Text] [Related]

  • 26. Torasemide for diuretic treatment of advanced chronic renal failure.
    Clasen W, Khartabil T, Imm S, Kindler J.
    Arzneimittelforschung; 1988 Jan; 38(1A):209-11. PubMed ID: 3285836
    [Abstract] [Full Text] [Related]

  • 27. Pharmacokinetics of torasemide and its metabolites in end-stage renal disease.
    Krämer BK, Schwab A, Braun N, Strutz F, Müller GA, Risler T.
    Eur J Clin Pharmacol; 1994 Jan; 47(2):157-9. PubMed ID: 7859803
    [Abstract] [Full Text] [Related]

  • 28. [Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?].
    Spannheimer A, Müller K, Falkenstein P, Reitberger U, Gutzwiller F, Follath F.
    Praxis (Bern 1994); 2002 Sep 11; 91(37):1467-75. PubMed ID: 12360682
    [Abstract] [Full Text] [Related]

  • 29. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats.
    Uechi M, Matsuoka M, Kuwajima E, Kaneko T, Yamashita K, Fukushima U, Ishikawa Y.
    J Vet Med Sci; 2003 Oct 11; 65(10):1057-61. PubMed ID: 14600341
    [Abstract] [Full Text] [Related]

  • 30. Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure.
    Ballester MR, Roig E, Gich I, Puntes M, Delgadillo J, Santos B, Antonijoan RM.
    Drug Des Devel Ther; 2015 Oct 11; 9():4291-302. PubMed ID: 26273191
    [Abstract] [Full Text] [Related]

  • 31. Mechanisms of reduced effects of loop diuretics in healthy volunteers and in patients with renal disease.
    Sjöström P.
    Scand J Urol Nephrol Suppl; 1988 Oct 11; 111():1-66. PubMed ID: 3201162
    [Abstract] [Full Text] [Related]

  • 32. The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.
    Knauf H, Spahn H, Mutschler E.
    Drugs; 1991 Oct 11; 41 Suppl 3():23-34. PubMed ID: 1712713
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of torasemide in patients with chronic heart failure.
    Achhammer I, Häcker W, Glocke M.
    Arzneimittelforschung; 1988 Jan 11; 38(1A):184-7. PubMed ID: 3285832
    [Abstract] [Full Text] [Related]

  • 34. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J.
    Aliment Pharmacol Ther; 2006 Sep 15; 24(6):973-82. PubMed ID: 16948809
    [Abstract] [Full Text] [Related]

  • 35. Torasemide. An update of its pharmacological properties and therapeutic efficacy.
    Dunn CJ, Fitton A, Brogden RN.
    Drugs; 1995 Jan 15; 49(1):121-42. PubMed ID: 7705212
    [Abstract] [Full Text] [Related]

  • 36. TORAFIC study protocol: torasemide prolonged release versus furosemide in patients with chronic heart failure.
    Díez J, Coca A, de Teresa E, Anguita M, Castro-Beiras A, Conthe P, Cobo E, Fernández E, TORAFIC Investigators Group.
    Expert Rev Cardiovasc Ther; 2009 Aug 15; 7(8):897-904. PubMed ID: 19673667
    [Abstract] [Full Text] [Related]

  • 37. Effects of prolonged-release torasemide versus furosemide on myocardial fibrosis in hypertensive patients with chronic heart failure: a randomized, blinded-end point, active-controlled study.
    TORAFIC Investigators Group.
    Clin Ther; 2011 Sep 15; 33(9):1204-1213.e3. PubMed ID: 21906812
    [Abstract] [Full Text] [Related]

  • 38. Dose-response curve for torasemide in healthy volunteers.
    Scheen AJ.
    Arzneimittelforschung; 1988 Jan 15; 38(1A):156-9. PubMed ID: 3370061
    [Abstract] [Full Text] [Related]

  • 39. Comparative effects of torasemide and furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Thandavarayan RA, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Feb 01; 75(3):649-59. PubMed ID: 18001696
    [Abstract] [Full Text] [Related]

  • 40. The impact of torasemide on haemodynamic and neurohormonal stress, and cardiac remodelling in heart failure - TORNADO: a study protocol for a randomized controlled trial.
    Balsam P, Ozierański K, Tymińska A, Główczyńska R, Peller M, Fojt A, Cacko A, Sieradzki B, Bakuła E, Markulis M, Kowalik R, Huczek Z, Filipiak KJ, Opolski G, Grabowski M.
    Trials; 2017 Jan 23; 18(1):36. PubMed ID: 28114980
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.